Medlab Group PTY LTD

About Medlab Group PTY LTD

The Medlab Group represents innovative technologies ready for commercial partnering:

1. NanoCelle: patented, nanomedicine delivery platform
2. Novel formulations to manipulate the human microbiome
3. market ready nutraceuticals.

Look at www.medlab.group for patent details, and prior publications.


Partnering enquiries welcome.

  • AU
  • 2024
    On CPHI since
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Primary activities
Clinical Research
Marketing Services Provider
Out-licensing specialist
Contact info
  • 164 Brook St, 2034, Coogee, Australia

Products from Medlab Group PTY LTD (3)

  • NanoCelle

    Product NanoCelle

     See https://www.medlab.group/what-is-nanocelle

    NanoCelle can be deployed in many molecules to enhance absorption, and increase patient compliance whilst reducing side effects.
  • NanoCelle B12

    Product NanoCelle B12

    B12 is a water-soluble compound, thus this foundation study was to determine NanoCelle® improvement in water-soluble compounds when compared to other more traditional forms, such as tablets, liquid emulsions, capsules, and liposomes.

    Study outcomes, published, and allowed TGA to approve hieighte...
  • NRGBiotic

    Product NRGBiotic

    The Product - NRGBIOTIC™

    PATENTED (2036), PUBLISHED CLINICAL DATA

    The successful research undertaken provided for a first-in-class probiotic for the treatment of major depressive disorder, and subsequent patents in global territories, see here.

    The formulation was entered into ...

Medlab Group PTY LTD Resources (2)

  • News MEDLAB GROUP - out-licencing and consultancy

    Medlab Group is a private company specialising in delivery platforms, the human microbiome, and food supplement out-licencing.
  • Video NanoCelle Introductory video - 2 min 40 sec runtime

    NanoCelle® is a unique, patented delivery system with diverse applications.
    QUICK FACTS

    Improves compound solubility

    Improves absorption

    Reduces compound side effects

    By-passes 1st pass metabolism

    Improves Patient compliance

    Improved onset

    Significant in vitro and in vivo data

    RESEARCH HAS SHOWN:

    Extensive studies have been conducted, and results differ with different compounds, but over 400,000 NanoCelle® products have been dosed to patients with minimal side effects.

    In vitro characterization done in collaboration with the University of Sydney

    PK studies showed up too 5 times more compound is absorbed when compared to tablets, capsules, emulsions, and liposomes

    Bioequivalence studies showed comparable levels to tablets 10x its dose.

    Phase 1/2 studies showed safety, tolerability, and efficacy.

    RWE Studies showed safety, tolerability, and efficacy over extended periods of time

    The research portfolio showed no reported incident of CARPA.